117 related articles for article (PubMed ID: 1686430)
1. [Use of polymerase chain reaction (PCR) as an additional diagnostic method in gynecologic oncology].
Czerwenka KF; Zeillinger R; Kury F; Manavi M; Speiser P; Peschke M; Steinhart U; Hosmann JW; Kubista E
Gynakol Rundsch; 1991; 31 Suppl 2():378-9. PubMed ID: 1686430
[No Abstract] [Full Text] [Related]
2. [C-erbB-2 oncogene amplification in breast cancer in correlation to steroid and epidermal growth factor receptor].
Manavi M; Czerwenka KF; Zeillinger R; Speiser P; Kury F; Steinhart U; Peschke M; Kubista E; Reinold E
Zentralbl Gynakol; 1992; 114(2):82-5. PubMed ID: 1350129
[TBL] [Abstract][Full Text] [Related]
3. Luminal B breast tumors are not HER2 positive.
Bhargava R; Dabbs DJ
Breast Cancer Res; 2008; 10(5):404; author reply 405. PubMed ID: 18831725
[No Abstract] [Full Text] [Related]
4. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
Rosser RJ
Cancer; 2003 Sep; 98(5):1102-3; author reply 1103. PubMed ID: 12942582
[No Abstract] [Full Text] [Related]
5. Altered gene expression in drug-resistant human breast cancer cells.
Wosikowski K; Schuurhuis D; Kops GJ; Saceda M; Bates SE
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2405-14. PubMed ID: 9815641
[TBL] [Abstract][Full Text] [Related]
6. [Cell receptors and proliferation markers in breast cancer].
Czerwenka KF; Schön HJ; Zeillinger R; Kubista E; Spona J
Gynakol Rundsch; 1989; 29 Suppl 2():400-1. PubMed ID: 2558992
[No Abstract] [Full Text] [Related]
7. [The effect of transport conditions on biochemically and immunohistochemically determined steroid hormone receptor content in breast cancer].
Remmele W; Schicketanz KH
Pathologe; 1993 Jan; 14(1):21-4. PubMed ID: 8383846
[No Abstract] [Full Text] [Related]
8. Amplification of the c-erb B-2 oncogene and prognosis of breast adenocarcinoma.
Heintz NH; Leslie KO; Rogers LA; Howard PL
Arch Pathol Lab Med; 1990 Feb; 114(2):160-3. PubMed ID: 1967929
[TBL] [Abstract][Full Text] [Related]
9. Histological type and marker expression of the primary tumour compared with its local recurrence after breast-conserving therapy for ductal carcinoma in situ.
Bijker N; Peterse JL; Duchateau L; Robanus-Maandag EC; Bosch CA; Duval C; Pilotti S; van de Vijver MJ
Br J Cancer; 2001 Feb; 84(4):539-44. PubMed ID: 11207051
[TBL] [Abstract][Full Text] [Related]
10. [Ductal carcinoma in situ: steroid receptors and proliferation kinetics].
Ronay G; Sponsel N; Tulusan AH
Pathologe; 1990 Nov; 11(6):327-31. PubMed ID: 1963219
[No Abstract] [Full Text] [Related]
11. Expression of epidermal growth factor receptor and c-erbB2 during the development of tamoxifen resistance in human breast cancer.
Newby JC; Johnston SR; Smith IE; Dowsett M
Clin Cancer Res; 1997 Sep; 3(9):1643-51. PubMed ID: 9815855
[TBL] [Abstract][Full Text] [Related]
12. [Incidence of amplification of the C-erb B2/Her-2/neu gene in human breast cancer].
Sellami M; Gamoudi M; Krichen K; Kharrat A; Ben Romdhane K; Maalej M
Arch Inst Pasteur Tunis; 1991; 68(1-2):33-41. PubMed ID: 1687309
[TBL] [Abstract][Full Text] [Related]
13. Decrease of c-erbB-2 and c-myc RNA levels in tamoxifen-treated breast cancer.
Le Roy X; Escot C; Brouillet JP; Theillet C; Maudelonde T; Simony-Lafontaine J; Pujol H; Rochefort H
Oncogene; 1991 Mar; 6(3):431-7. PubMed ID: 1707153
[TBL] [Abstract][Full Text] [Related]
14. Expression of the c-erbB-2 gene product as detected in cytologic aspirates in breast cancer.
Allan SM; Fernando IN; Sandle J; Trott PA
Acta Cytol; 1993; 37(6):981-2. PubMed ID: 7902634
[No Abstract] [Full Text] [Related]
15. Correlation between the expression of apoptosis-related bcl-2 and p53 oncoproteins and the carcinogenesis and progression of breast carcinomas.
Zhang GJ; Kimijima I; Abe R; Kanno M; Katagata N; Hara K; Watanabe T; Tsuchiya A
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2329-35. PubMed ID: 9815631
[TBL] [Abstract][Full Text] [Related]
16. Differences in the pathologic and molecular features of intraductal breast carcinoma between younger and older women.
Rodrigues NA; Dillon D; Carter D; Parisot N; Haffty BG
Cancer; 2003 Mar; 97(6):1393-403. PubMed ID: 12627502
[TBL] [Abstract][Full Text] [Related]
17. Problems and solutions in the evaluation of hormone receptors in breast cancer.
Allred DC
J Clin Oncol; 2008 May; 26(15):2433-5. PubMed ID: 18487563
[No Abstract] [Full Text] [Related]
18. Comparison of differential PCR and immunohistochemistry for the evaluation of c-erbB-2 in breast carcinoma and relationship to other prognostic factors.
Erdogan S; Ergin M; Tuncer I
Neoplasma; 2003; 50(5):326-30. PubMed ID: 14628084
[TBL] [Abstract][Full Text] [Related]
19. Oncogene patterns in breast and ovarian carcinomas.
Csókay B; Papp J; Besznyák I; Bösze P; Sárosi Z; Tóth J; Zalay Z; Oláh E
Eur J Surg Oncol; 1993 Dec; 19(6):593-9. PubMed ID: 7903645
[TBL] [Abstract][Full Text] [Related]
20. Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy.
Esteva FJ; Sahin AA; Cristofanilli M; Coombes K; Lee SJ; Baker J; Cronin M; Walker M; Watson D; Shak S; Hortobagyi GN
Clin Cancer Res; 2005 May; 11(9):3315-9. PubMed ID: 15867229
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
